Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2881–2904 of 3,774 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Arm 3 intervention Clear all

Conditions: Cardiopulmonary, Exercise
Interventions: COSMED K5 CPET (Cardiopulmonary Exercise Test), ParvoMedics CPET; Device
Lead sponsor: Baylor Research Institute; Other
Eligibility: 20 Years to 29 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Frisco, Texas

Conditions: Cardiometabolic Risk Factors in Adult Wheelchair Users
Interventions: Instructor-led, one-on-one M2M exercise group, Self-guided control with pre-recorded standard exercise videos; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 89 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Headache
Interventions: Audit-feedback, Clinical Decision Support; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM), CKD Stage 3, CKD Stage 4, CKD Stage 5, Diabetes Mellitus, Diabetic Kidney Disease
Interventions: PLAFOND diet; Dietary Supplement
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Orange, California • Torrance, California

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions: Exercise Intervention, Informational Intervention, Nutritional Assessment, Physical Performance Testing, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 65 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Human Papillomavirus Vaccination, Emotions
Interventions: Cancer survivor narrative, Healthy eating tips; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Chronic Renal Insufficiency
Interventions: Aerobic Exercise Training; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Lactating Women
Interventions: Lusedra, Propofol; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Cutaneous T Cell Lymphoma, Mycosis Fungoides
Interventions: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system; Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Anemia
Interventions: Standard of Care, Informational Series and follow-up support; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 55 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Detroit, Michigan

Conditions: End Stage Renal Disease, Living Donor Kidney Transplantation, Renal Dialysis
Interventions: COACH (Communicating about Choices in Transplantation); Behavioral
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: PrEP Adherence, Methamphetamine Use Disorder, HIV
Interventions: CHAMPION Intervention, Delayed CHAMPION Package; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Spinal Cord Injuries, Trauma, Nervous System
Interventions: MyndMove®, Conventional Therapy; Device · Other
Lead sponsor: MyndTec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Cleveland, Ohio • Houston, Texas

Conditions: Triple Negative Breast Cancer
Interventions: Paclitaxel, Carboplatin, Nivolumab, Cabiralizumab, Tumor biopsy, Bone marrow, Blood draw; Drug · Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Stroke, Upper Extremity Hemiparesis
Interventions: priming and task specific training; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 55 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Prostate Cancer
Interventions: Blood draw, Urine sample; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Breast Cancer
Interventions: PF-07248144, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 215
States / cities: Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more

Conditions: Glioma
Interventions: Rhenium Liposome Treatment; Drug
Lead sponsor: Cerenome; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 4
States / cities: Manhasset, New York • Columbus, Ohio • Dallas, Texas + 1 more

Conditions: Bronchiolitis, Bronchodilator Agents
Interventions: Albuterol Sulfate, 2.5 Mg/3 mL (0.083%) Inhalation Solution, Sodium Chloride 0.9% Inhl 3Ml; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 3 Months to 24 Months
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Contraception
Interventions: SpeakOut, Alcohol Control Intervention; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 19 Years · Female only
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Davis, California • Los Angeles, California

Conditions: Retinitis Pigmentosa
Interventions: Sub-Retinal Administration of OCU400-301; Genetic
Lead sponsor: Ocugen; Industry
Eligibility: 3 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Opioid-Related Disorders, Benzodiazepine-Related Disorders, Falls Injury
Interventions: Educational Intervention; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 65 Years and older
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: KSI-301, Aflibercept, Sham Procedure; Drug · Other
Lead sponsor: Kodiak Sciences Inc; Industry
Eligibility: 18 Years and older
Enrollment: 568 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 81
States / cities: Phoenix, Arizona • Beverly Hills, California • Fresno, California + 75 more

Conditions: Colorectal Neoplasms
Interventions: Standard Information, Preference-tailored Information; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 50 Years to 78 Years
Enrollment: 466 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Search by objective public record fields.

COSMED K5 Validation and Reliability Study

Cardiometabolic Health Intervention Using Movement-to-Music Exercise

Equity in Diagnostic Imaging Trial

Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease

Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial

Stories to Prevent (StoP) HPV Cancers

Exercise and Vascular Function in Chronic Kidney Disease

A Study to Assess the Transfer of Fospropofol and Its Active Metabolite, Propofol, to Breast Milk Following Administration of LUSEDRA to Lactating Women Undergoing a Needed Procedure

Photopheresis in Early-stage Mycosis Fungoides

Menstruation and Anemia Research: A Community Health Study

Social Networks and Renal Education: Promoting Transplantation

CHAMPION: Combining HIV And Meth Prevention and Treatment Interventions Optimized for HIV-Negative MSM

Restoration of Reaching and Grasping Function in Individuals With Spinal Cord Injury Using MyndMove® Neuromodulation Therapy

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Bilateral Priming for Upper Extremity Hemiparesis in Older Adults

Investigating and Characterizing the Immune Response to Prostate Cancer

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Characterization of Bronchodilator Response in Children With Bronchiolitis Using Phenotypic and Genotypic Features

The Share Health Study: Teen Social Connections and Health

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

De-prescribing Program to Evaluate Falls in Older Adults

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

Evaluating a Preference-based Intervention for Increasing Colorectal Cancer Screening